| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003693A1 Pharmaceutical composition containing fenofibrate and preparation method |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003684A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 01/18/2001 | WO2001003680A2 Compounds for inhibiting diseases and preparing cells for transplantation |
| 01/18/2001 | WO2000063415A8 Dna encoding the human vanilloid receptor vr1 |
| 01/18/2001 | WO2000057918A3 Novel formulations comprising lipid-regulating agents |
| 01/18/2001 | WO2000024360A8 Preparation and use of solidified oils |
| 01/18/2001 | WO2000002911A3 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/18/2001 | WO1999050403A3 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses |
| 01/18/2001 | CA2680437A1 Peptides that lower blood glucose levels |
| 01/18/2001 | CA2379149A1 Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378610A1 Human eag2 |
| 01/18/2001 | CA2378600A1 Amino ceramide-like compounds and therapeutic methods of use |
| 01/18/2001 | CA2378595A1 Benzoylpyridazines |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378562A1 Method for producing oligopolysaccharides |
| 01/18/2001 | CA2378515A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | CA2378291A1 Quinazoline derivatives |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377999A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | CA2377760A1 Process for the preparation of tricyclic amino alcohol derivatives |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | CA2375628A1 Compounds for inhibiting diseases and preparing cells for transplantation |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1068221A2 Template associated npy y2-receptor agonists |
| 01/17/2001 | EP1068212A1 THIAZOLO 4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| 01/17/2001 | EP1068207A1 AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
| 01/17/2001 | EP1068206A1 Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
| 01/17/2001 | EP1068205A1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1067967A1 A drug composition containing sodium pravastatin |
| 01/17/2001 | EP1067945A2 Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions |
| 01/17/2001 | EP1067925A1 Antidiabetic agents |
| 01/17/2001 | EP1067894A2 Protease inhibitors |
| 01/17/2001 | CN1280570A Substituted fused heterocyclic compounds |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280561A Amidocarboxylic acid derivatives |
| 01/17/2001 | CN1280501A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/17/2001 | CN1280500A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/17/2001 | CN1280010A Oral medicine for curing diabetes and its producing method |
| 01/17/2001 | CN1280007A Jew's-ear blood fat regulating capsule |
| 01/17/2001 | CN1279989A Natutal medicine for reducing weight and its making method |
| 01/17/2001 | CN1279978A Ginkgo and gastrodia taber capsule |
| 01/17/2001 | CN1279970A Antilipemic blood circulation promoting xueluofu capsale |
| 01/17/2001 | CN1279964A Method for removing farm chemical ingredients from ginseng extract |
| 01/17/2001 | CN1279949A Compound hypoglycemic nutrient |
| 01/17/2001 | CN1279948A Hypoglycemic for type II diabetes |
| 01/17/2001 | CN1060679C Use of combination of angiotensin-converting enzyme inhibitor and calcium antagonist for treatment of proteinuria |
| 01/16/2001 | USRE37020 Administering an elderly patient a protein source, a lipid source includes triglycerides and a carbohydrate source includes a source of dietary fiber, preferably, the protein source includes atleast 18% of the total calories as |
| 01/16/2001 | US6175021 Human non-pancreatic secretory phospholipase a2 (spla2); inhibits release of arachidonic acid to treat septic shock; ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1h-indol-4 -yl)oxylacetic acid, for example |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174993 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 01/16/2001 | US6174925 Reducing insulin resistance in humans in whom impaired glucose tolerance or non-insulin dependent diabetes mellitus have not presented but in whom there is increased risk of developing such conditions by administering sibutramine analogue |
| 01/16/2001 | US6174910 Treating pathological symptoms of vascular proliferation disorders which can be reduced or inhibited by apoptosis, by administering at.sub.1(angiotensin) receptor antagonist compound such as valsartan, irbesartan, losatran etc. |
| 01/16/2001 | US6174904 Treating glycometabolism disorders in mammals by administering therapeutically effective amount of an insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor |
| 01/16/2001 | US6174883 3-substituted-2-oxindoles derivatives |
| 01/16/2001 | US6174874 Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B) |
| 01/16/2001 | US6174857 Parenteral mixture comprising insulin-like growth factor i, a bone antiresorptive compound and a carrier |
| 01/16/2001 | US6174856 Stabilized insulin compositions |
| 01/16/2001 | US6174560 Substance for lowering high cholesterol level in serum and methods for preparing and using the same |
| 01/16/2001 | US6174543 Antidiabetic external skin application composition |
| 01/16/2001 | US6174527 Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
| 01/16/2001 | CA2314008A1 2-benzimidazolylamine compounds as orl1-receptor agonists |
| 01/16/2001 | CA2029861C Diagnosis and treatment of insulin dependent diabetes mellitus |
| 01/11/2001 | WO2001002598A2 Screening for compounds modulating mitochondrial proton leak |
| 01/11/2001 | WO2001002571A2 An interleukin-1 receptor antagonist and uses thereof |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002560A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | WO2001002410A1 Novel process |
| 01/11/2001 | WO2001002406A1 Potassium channel blocking agents |
| 01/11/2001 | WO2001002405A1 Quinuclidine derivatives for treatment of neurological disorders |
| 01/11/2001 | WO2001002400A1 Fused imidazole compounds and remedies for diabetes mellitus |
| 01/11/2001 | WO2001002399A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | WO2001002396A1 Novel benzo[f]naphthyridine, preparation and compositions containing them |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002379A1 Selective npy (y5) antagonists |
| 01/11/2001 | WO2001002373A1 Dihydrobenzodiazepins and their use for treating dyslipidemia |
| 01/11/2001 | WO2001002369A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2001 | WO2001002368A1 N-heterocyclic derivatives with neuronal activity |
| 01/11/2001 | WO2001002361A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002016A1 Nasogastric enteral formulations |
| 01/11/2001 | WO2001002012A1 Remedies for drug-resistant hypercalcemia |
| 01/11/2001 | WO2001002011A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001973A2 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001969A2 Methods of treating and/or suppressing weight gain |
| 01/11/2001 | WO2001001968A2 Methods and compositions for regulating gut motility and food intake |
| 01/11/2001 | WO2001001963A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001962A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001940A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 01/11/2001 | WO2000061189A3 Water-soluble compositions of bioactive lipophilic compounds |
| 01/11/2001 | WO2000059515A3 Immunomodulating polymers |
| 01/11/2001 | WO2000058466A3 Protease resistant flint analogs |
| 01/11/2001 | WO2000054729A3 Heterocyclic aromatic compounds useful as growth hormone secretagogues |